PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: rfXcel Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

rfXcel Corporation Partners with Secure Symbology to Offer Complete Drug Pedigree and Serialization Solution - rfXcel’s most Production-Proven E-Pedigree Solution and Secure Symbology’s patented Serialization System to offer “Turnkey” Compliance to California Pedigree Legislation
rfXcel Corporation Partners with Secure Symbology to Offer Complete Drug Pedigree and Serialization Solution

 

NewswireToday - /newswire/ - San Ramon, CA, United States, 2008/02/24 - rfXcel’s most Production-Proven E-Pedigree Solution and Secure Symbology’s patented Serialization System to offer “Turnkey” Compliance to California Pedigree Legislation.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

rfXcel Corporation, a leading provider of ePedigree Management solutions that allow manufacturers, distributors, and retailers to track the chain of custody of prescription drugs through the pharmaceutical supply chain, today announced that it has entered into a partnership agreement with Secure Symbology, Inc. (SSI), a leading provider of Serialization Systems, to offer an integrated, comprehensive, EPC-Based ePedigree, Serialization, and Track and Trace System.

Beginning with California and its 2009 deadline, states are mandating the serialization and tracking of all pharmaceuticals moving in and out of their borders. California has mandated that pharmaceutical packaging, starting at the unit-of-sale level, must be marked with unique serial numbers. It also requires that an electronic pedigree for pharmaceutical packages must be created by the manufacturer, and then maintained and communicated down the supply chain to the retail level.

rfXcel’s ePedigree Management System and SSI’s Serialization System are 100% compliant with California’s impending 2009 regulation. Each unit-of-sale and each level of aggregation is serialized, and an electronic pedigree is created for the manufacturer’s trading partners.

“Pharmaceutical Manufacturers are looking for a “turnkey” ePedigree and Serialization System that is tightly integrated and available for immediate deployment, said Kamal Mustafa, President of SSI. “We’re excited to be partnering with the industry’s most production-proven ePedigree Management System Supplier in providing a solution to secure the pharmaceutical supply chain from the threat of counterfeits”.

“I’m delighted to announce this partnership with SSI to provide our mutual customers with a complete solution to meet the California mandate”, said Glenn Abood, Founder and CEO at rfXcel. “Combining our solution with SSI’s serialization suite, with its patented serialization methodologies and patent pending data vault, we offer a unique solution that can be seamlessly integrated into any manufacturer’s production line”.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: rfXcel Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


rfXcel Corporation Partners with Secure Symbology to Offer Complete Drug Pedigree and Serialization Solution

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Jim Ensell - rfXcel.com 
925-325-0584 jensell[.]rfxcel.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any rfXcel Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From rfXcel Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)